Humanized cxcr3 antibodies with depleting activity and methods of use thereof

A humanization, antibody technology, applied in chemical instruments and methods, medical preparations containing active ingredients, antibodies, etc.

Inactive Publication Date: 2020-03-24
SANOFI SA
View PDF20 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, T1D has a significant chronic disease burden and remains a major public health problem worldwide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Humanized cxcr3 antibodies with depleting activity and methods of use thereof
  • Humanized cxcr3 antibodies with depleting activity and methods of use thereof
  • Humanized cxcr3 antibodies with depleting activity and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0300] Example 1: Generation of Humanized Anti-CXCR3 Monoclonal Antibody

[0301] Anti-CXCR3 monoclonal antibodies were generated as described in WO2013 / 109974. Humanized clone 53 monoclonal antibody was generated as described below.

[0302] A humanized version of clone 53 capable of directing depletion of CXCR3 expressing cells was prepared. A humanized clone 53 monoclonal antibody with the VH and VK sequences shown in Table 4 was generated.

[0303] Germinal Index scores for each humanized variant shown in Table 4. The heavy chain was compared to the IGHV3-23*03 / IGHJ4*03 germline sequence; the light chain was compared to the IGKV1-9*01 / IGKJ2*01 germline sequence.

[0304] Table 4

[0305] Hu antibody VH SEQ ID NO VL SEQ ID NO Hair Growth Index 1 a

Hair Growth Index 2 b

23 18 21 0.885 0.950 24 19 21 0.872 0.933 25 20 21 0.877 0.939 26 18 22 0.890 0.955 27 19 22 0.877 0.939 29 20 22 0.881 0.944 ...

Embodiment 2

[0321] Example 2: CDR optimization

[0322] Many VH CDR and / or VL CDR variants were prepared. Binding affinity to recombinant human CXCR3 was measured using Biacore. Mutants with at least as strong binding as 53Hu37 are shown in Table 3.

Embodiment 3

[0323] Example 3: CXCR3-173 is a depleting antibody

[0324] Hamster anti-mouse CXCR3 monoclonal (clone CXCR3-173) was used as a surrogate antibody in preclinical experiments. CXCR3-173 has been previously described as a blocking antibody that does not deplete CD4+ T cells in vivo. (See Uppaluri et al., Transplantation 86:137-47 (2008)).

[0325] The following Fc variants of hamster CXCR3-173 mAb were prepared to test the effector function of the antibody: aglycosylated N297G variant of mouse IgG1 (CXCR3 mIgG1 agly); wild-type mouse IgG2a chimera (CXCR3 mIgG2a WT); Modified to eliminate capacity-depleting mouse IgG2a chimera (CXCR3 mIgG2a Dab); and wild-type mouse IgG3 (CXCR3mIgG3).

[0326] C57BL / 6 mice (Jackson Laboratories, n=5 per group) aged 8 to 10 weeks were given a single 5 mg / kg intravenous dose of antibody and blood was harvested 24 hours later for flow cytometry using the following markers Cytometry analysis: CD4 and CD8 T cells were analyzed by TCRab, CD4 and CD...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided are humanized CXCR3 antibodies and methods of using the antibodies to treat CXCR3-associated disorders such as type 1 diabetes mellitus (TID), particularly new-onset TID, and psoriasis. In certain embodiments, the anti-CXCR3 antibodies are humanized anti-human CXCR3 antibodies with enhanced effector function against cells expressing CXCR3 on their surface. Also provided are nucleic acid sequences encoding the antibodies, and pharmaceutical compositions comprising the antibodies.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 437,867, filed December 22, 2016, and European Patent Application No. 17305042.8, filed January 21, 2017, the entire contents of which are incorporated herein by reference. technical field [0003] Provided are humanized anti-CXCR3 antibodies and methods of using the antibodies to treat disorders associated with CXCR3 signaling, such as type 1 diabetes (diabetes mellitus type 1 / type 1 diabetes mellitus (T1D)) and psoriasis. Background technique [0004] Type 1 diabetes is characterized by the inability to produce sufficient insulin to maintain glucose homeostasis. This disorder is thought to result from autoimmune-mediated destruction of pancreatic beta cells. Autoimmunity associated with type 1 diabetes involves the involvement of B and T autoreactive lymphocytes. The development of type 1 diabetes may be mediated by autoreactive T cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61P37/06
CPCC07K16/2866A61K2039/505C07K2317/14C07K2317/24C07K2317/41C07K2317/52C07K2317/524C07K2317/56C07K2317/565C07K2317/72C07K2317/73C07K2317/76C07K2317/90C07K2317/92C07K2317/94A61P37/06A61P17/06A61P3/10A61K38/195C07K2317/732A61K39/395
Inventor W·布朗迪克R·丘T·D·康纳斯S·帕克H·邱M·尤德
Owner SANOFI SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap